JP2016513647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513647A5 JP2016513647A5 JP2016502054A JP2016502054A JP2016513647A5 JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5 JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bimatoprost
- administered
- composition according
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 12
- 229960002470 bimatoprost Drugs 0.000 claims 12
- 102000016267 Leptin Human genes 0.000 claims 3
- 108010092277 Leptin Proteins 0.000 claims 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 3
- 229940039781 leptin Drugs 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793132P | 2013-03-15 | 2013-03-15 | |
| US61/793,132 | 2013-03-15 | ||
| PCT/US2014/026110 WO2014143629A1 (en) | 2013-03-15 | 2014-03-13 | Bimatoprost for enhancement of leptin production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513647A JP2016513647A (ja) | 2016-05-16 |
| JP2016513647A5 true JP2016513647A5 (enExample) | 2017-04-13 |
Family
ID=50442712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502054A Pending JP2016513647A (ja) | 2013-03-15 | 2014-03-13 | レプチン生産を増進するビマトプロスト |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140275272A1 (enExample) |
| EP (1) | EP2968361A1 (enExample) |
| JP (1) | JP2016513647A (enExample) |
| KR (1) | KR20150129735A (enExample) |
| CN (1) | CN105338985A (enExample) |
| AU (1) | AU2014228307A1 (enExample) |
| BR (1) | BR112015021859A2 (enExample) |
| CA (1) | CA2901529A1 (enExample) |
| HK (1) | HK1220385A1 (enExample) |
| RU (1) | RU2015134772A (enExample) |
| WO (1) | WO2014143629A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102159427B1 (ko) | 2015-04-30 | 2020-09-24 | 알러간, 인코포레이티드 | 지방 감소를 위한 미용적 방법 및 치료적 용도 |
| WO2026072679A1 (en) * | 2024-09-25 | 2026-04-02 | Manistee Therapeutics Inc. | Methods and compositions for the delivery of prostaglandin f2a analogs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO2007111806A2 (en) * | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| RU2482851C2 (ru) * | 2009-02-20 | 2013-05-27 | Микро Лабс Лимитед | Хранение стабильного продукта простагландина |
| CA2824317C (en) * | 2011-01-19 | 2014-12-16 | Terakine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
-
2014
- 2014-03-13 KR KR1020157025059A patent/KR20150129735A/ko not_active Withdrawn
- 2014-03-13 RU RU2015134772A patent/RU2015134772A/ru not_active Application Discontinuation
- 2014-03-13 JP JP2016502054A patent/JP2016513647A/ja active Pending
- 2014-03-13 EP EP14716168.1A patent/EP2968361A1/en not_active Withdrawn
- 2014-03-13 BR BR112015021859A patent/BR112015021859A2/pt active Search and Examination
- 2014-03-13 AU AU2014228307A patent/AU2014228307A1/en not_active Abandoned
- 2014-03-13 HK HK16108521.3A patent/HK1220385A1/zh unknown
- 2014-03-13 US US14/209,099 patent/US20140275272A1/en not_active Abandoned
- 2014-03-13 CN CN201480012846.5A patent/CN105338985A/zh active Pending
- 2014-03-13 WO PCT/US2014/026110 patent/WO2014143629A1/en not_active Ceased
- 2014-03-13 CA CA2901529A patent/CA2901529A1/en not_active Abandoned
-
2015
- 2015-11-25 US US14/952,208 patent/US20160310505A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377629B (es) | Composiciones farmacéuticas tópicas. | |
| JP2014505733A5 (enExample) | ||
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| JP2017503798A5 (enExample) | ||
| JP2015155440A5 (enExample) | ||
| FR3024037B1 (fr) | Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques | |
| MX378007B (es) | Derivados de biarilo como agonistas de gpr120. | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| WO2011147536A3 (en) | Topical pharmaceutical compositions comprising mometasone furoate | |
| JP2020504178A5 (enExample) | ||
| ATE522224T1 (de) | Medizinisches kräuterextrakt mit wirkung gegen adipositas | |
| WO2015121457A8 (en) | Fgf-8 for use in treating diseases or disorders of energy homeostasis | |
| JP2018536638A5 (enExample) | ||
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| JP2014530223A5 (enExample) | ||
| RU2015134772A (ru) | Применение биматопроста для повышения выработки лептина | |
| JP2014101346A5 (enExample) | ||
| WO2011151786A3 (en) | Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |